Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
This is precisely where StockStory comes in - our job is to find you high-quality companies that can win regardless of the conditions. That said, here are three large-cap stocks that still have big upside potential.
Analog Devices (ADI)
Market Cap: $202.1 billion
Founded by two MIT graduates, Ray Stata and Matthew Lorber in 1965, Analog Devices (NASDAQ: ADI) is one of the largest providers of high performance analog integrated circuits used mainly in industrial end markets, along with communications, autos, and consumer devices.
Why Are We Fans of ADI?
- Impressive 16.4% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Operating profits increased over the last five years as the company gained some leverage on its fixed costs and became more efficient
- Robust free cash flow margin of 35.5% gives it many options for capital deployment, and its growing cash flow gives it even more resources to deploy
Analog Devices’s stock price of $416.18 implies a valuation ratio of 25.4x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
EMCOR (EME)
Market Cap: $34.7 billion
Through its network of over 70 subsidiaries, EMCOR (NYSE: EME) provides electrical, mechanical, and building construction and services
Why Do We Love EME?
- Impressive 16.3% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Share buybacks catapulted its annual earnings per share growth to 35.7%, which outperformed its revenue gains over the last two years
- Improving returns on capital reflect management’s ability to monetize investments
At $780.15 per share, EMCOR trades at 22.1x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stryker (SYK)
Market Cap: $105.6 billion
With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.
Why Could SYK Be a Winner?
- Core business is healthy and doesn’t need acquisitions to boost sales as its organic revenue growth averaged 9.2% over the past two years
- Economies of scale give it some operating leverage when demand rises
- Free cash flow margin jumped by 6.5 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
Stryker is trading at $275.30 per share, or 17.1x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
